|MDACC Study No:||2010-0736 (clinicaltrials.gov NCT No: NCT01272245)|
|Title:||A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|
|Principal Investigator:||Hagop Kantarjian|
|Treatment Agent:||Cytarabine; Omacetaxine Mepesuccinate|
|Study Description:||The goal of this clinical research study is to learn if omacetaxine given with |
cytarabine can help to control the disease in patients with AML or high-risk
MDS. The safety of the study drugs will also be studied.